Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874622 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNABRD4HPGDSNR4A2 | |
| SCHEMBL27519023 | 0.87 | HPGDS (0.48) | ALDH1A1LMNABRD4HPGDSNR4A2 | |
| SCHEMBL31497570 | 0.86 | BRD4 (0.49) | ALDH1A1LMNABRD4NR4A2CREBBP | |
| SCHEMBL12419944 | 0.86 | BRD4 (0.53) | ALDH1A1LMNABRD4NR4A2CREBBP | |
| SCHEMBL2650431 | 0.86 | BRD4 (0.49) | ALDH1A1LMNABRD4NR4A2CREBBP | |
| SCHEMBL30917342 | 0.84 | TSHR (0.56) | ALDH1A1LMNATSHRKDM4EHSD17B10 | |
| SCHEMBL18095299 | 0.84 | TSHR (0.56) | ALDH1A1LMNATSHRKDM4EHSD17B10 | |
| SCHEMBL29434198 | 0.84 | BRD4 (0.59) | ALDH1A1LMNABRD4NR4A2CREBBP | |
| SCHEMBL70381 | 0.84 | BRD4 (0.59) | ALDH1A1LMNABRD4NR4A2CREBBP | |
| SCHEMBL6018021 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LMNABRD4NR4A2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4446323-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | Shanghai Visonpharma Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118047780-A | Quinazoline heterocyclic compound and anti-infection and anti-tumor application thereof | 中国医学科学院药物研究所 | 2024-05-17 | — | — | CN | disclosed |
| CN-117886695-A | Synthesis method of aforana key intermediate 4-formyl-1-methyl naphthoate | 浙江工业大学 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023104165-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | 上海维申医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-112996529-A | Matriptase 2 inhibitor and application thereof | 迪斯克医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-1994000120-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993003722-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4052433-A | INTERMEDIATES FOR BENZOFURANS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4016195-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3994879-A | CONDENSING AZOMETHINES, OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
| US-3957846-A | OPTICAL BRIGHTENERS, LACQUERS, SYNTHETIC FIBERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | ALDH1A1 3877/4885LMNA 1207/4885BRD4 3801/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | ALDH1A1 3877/4885LMNA 1207/4885BRD4 3801/4885 |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | TLR7, TLR8, TLR1 | ALDH1A1 2284/4885LMNA 3044/4885BRD4 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.